CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 47,652 shares at an average $41.31 ($1,968,352)
- 4 Option exercise Chief Scientific Officer acquired 6,500 shares (option exercise)
- 4 Open-market sale Chief Scientific Officer sold 2,650 shares at an average $50.98 ($135,087)
- 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $50.99 ($50,990)
- 4 Open-market sale Director sold 19,415 shares at an average $49.07 ($952,613)
- 4 Open-market sale Director sold 28,236 shares at an average $49.71 ($1,403,553)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Medical Officer sold 1,000 shares at $50.15 ($50,150)
- 4 Open-market sale Chief Scientific Officer sold 2,650 shares at $50.00 ($132,500)
- 4 Open-market sale Director sold 47,651 shares at an average $57.27 ($2,728,849)
- 4 Open-market sale Chief Medical Officer sold 1,000 shares at an average $59.93 ($59,926)
- 4 Open-market sale Chief Scientific Officer sold 5,300 shares at an average $60.00 ($318,026)
- 4 Open-market sale Director sold 9,298 shares at an average $58.81 ($546,840)
Page 8 of 11 · 207 filings